Yescarta
Axicabtagene Ciloleucel
Disease: Large B-cell Lymphoma
Indication: Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.
Company: Kite Pharma
Private Company
Notable Transactions: Gilead acquired Kite Pharma for $12B
Methods: The patient sits for leukapheresis, and the product is sent to a lab. There, the T cells are genetically enhanced to attack cancerous cells and expanded.
Link to the clinical trial: NCT02348216
Link to company R&D pipeline: https://www.kitepharma.com/science-medicine/pipeline
Package Insert: https://www.fda.gov/media/108377/download
Current Phase: FDA Approved
Subscribe to Our Newsletter
Subscribe to our newsletter to keep up to date with all the latest news about AGT!
[formidable id=9]
